Bjarte Almas

Papers

1

Total Citations

3

H-Index

1

About

Bjarte Almas is a leading urologic oncologist whose work centers on testicular cancer, particularly seminoma management and the refinement of surgical staging and treatment protocols. As a key member of the SWENOTECA (Swedish Norwegian Testicular Cancer Group), Almas has been instrumental in advancing primary retroperitoneal lymph node dissection (RPLND) for seminoma stage IIA-IIB, challenging traditional reliance on chemotherapy or radiotherapy. His most-cited paper, "The Early Results of the SWENOTECA Introduction of Primary RPLND in Seminoma Stage IIA-IIB ≤ 3cm" (2023), reports on a paradigm-shifting approach that aims to reduce long-term toxicity while maintaining excellent oncologic outcomes. This work has already garnered significant attention, reflecting its impact on clinical practice. Almas’s contributions are pivotal in personalizing treatment for young men with testicular cancer, emphasizing surgical precision and survivorship. His research continues to shape international guidelines, offering patients a tailored, less morbid path to cure.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
MP33-04 THE EARLY RESULTS OF THE SWENOTECA (SWEDISH NORWEGIAN TESTICULAR CANCER GROUP) INTRODUCTION OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN SEMINOMA STAGE IIA-IIB ≤ 3cm
3 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 13

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago